Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine

LYB001 is an innovative recombinant SARS-CoV-2 vaccine that displays a repetitive array of the spike glycoprotein’s receptor-binding domain (RBD) on a virus-like particle (VLP) vector to boost the immune system, produced using Covalink plug-and-display protein binding technology. LYB001’s safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, Xiaolan, Liu, Jun, Zeng, Ying, Nie, Jing, Cui, Xuelian, Wang, Tao, Wang, Yilin, Chen, Yiyong, Kang, Wei, Yang, Zhonghua, Liu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588526/
https://www.ncbi.nlm.nih.gov/pubmed/37854013
http://dx.doi.org/10.1080/21645515.2023.2267869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588526/
https://www.ncbi.nlm.nih.gov/pubmed/37854013
http://dx.doi.org/10.1080/21645515.2023.2267869

Ejemplares similares